Claim: The AFIB Technology has been tested by clinical studies and the blood pressure monitor which uses AFIB Technology is being tested for sensitivity from Microlife, founded in 1981 whose headquarters are in Taiwan.
Evidence: It has been the subject of numerous medical studies and has been validated for in-home and clinical use. Several clinical studies have tested the Microlife AFIB Technology against 12-lead electrocardiography (ECG) interpreted by cardiologists. In virtually every study, researchers have concluded that Microlife's AFIB Technology is suitable for use as an atrial fibrillation detection system for in-home and/or clinical purposes. AFIB Technology (sometimes referred to as Microlife AFIB Technology) is a feature in sphygmomanometer devices that is designed to detect and monitor the incidence of atrial fibrillation in patients. The technology was designed, patented, and is currently used by the Microlife Corporation. One study indicated that the Microlife blood pressure monitor had a sensitivity for detecting atrial fibrillation of 100%, a specificity of 92%. The sensitivity for detection in these studies varied between 95 and 100% with specificity values of 89 to 92%. 
A sphygmomanometer, also known as a blood pressure monitor, or blood pressure gauge, is a device used to measure blood pressure, composed of an inflatable cuff to collapse and then release the artery under the cuff in a controlled manner, and a mercury or aneroid manometer to measure the pressure. A sphygmomanometer consists of an inflatable cuff, a measuring unit (the mercury manometer, or aneroid gauge), and a mechanism for inflation which may be a manually operated bulb and valve or a pump operated electrically. 
Microlife was founded in Taipei, Taiwan in 1981. Microlife Corporation Taipei, Taiwan 1981 (1981) Microlife's blood pressure monitors and the technologies they house have been the subject of numerous studies and have been validated for both clinical and home use.